Drivers of Implementation of Recombinant Technologies for Endotoxin Testing

[Article Title]

As documented by the most recent US Pharmacopeia announcement, the adoption of recombinant technologies for endotoxin testing is gaining momentum in the pharmaceutical industry. This article explores the fundamentals of using recombinant Cascade Reagents (rCR), their analytical performance and equivalency to LAL reagents, current developments within the regulatory framework (specifically updates provided by the USP and the factors accelerating their implementation). Download this white paper now to learn more.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.